Forbes November 23, 2021
Legal psychedelic medicine is poised to soon disrupt the multibillion-dollar mental health field. Treatments being trialed today in clinical settings using substances like psilocybin-containing mushrooms will soon offer legal alternatives to the more than 50 percent of patients receiving therapy for major depressive disorder (MDD) who do not respond to approved depression medications.
As psychedelic substances meet with ever-decreasing resistance from the public — evidenced by the growing number of U.S. cities passing decriminalization laws — the reality of adding psychedelic treatments to the mental health landscape is coming sharper into focus. Along with creating more opportunities of care for patients, the creation of new effective therapies will likely put pressure on healthcare providers to examine the upside of psychedelic...
Today's Sponsors
Today's Sponsor